Cargando…

Treatment for clear cell carcinoma of the abdominal wall at a tertiary cancer center

Clear cell carcinoma (CCC) of the abdominal wall is a rare and agressive disease. We aim to elucidate the clinical and prognostic characteristics of this disease. Medical records of ten patients diagnosed with CCC of the abdominal wall at Fudan University Shanghai Cancer Center were reviewed. We ill...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Zheng, Wen, Hao, Ju, Xingzhu, Bi, Rui, Chen, Xiaojun, Yang, Wentao, Wu, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233660/
https://www.ncbi.nlm.nih.gov/pubmed/35752641
http://dx.doi.org/10.1038/s41598-022-14917-0
_version_ 1784735841412710400
author Feng, Zheng
Wen, Hao
Ju, Xingzhu
Bi, Rui
Chen, Xiaojun
Yang, Wentao
Wu, Xiaohua
author_facet Feng, Zheng
Wen, Hao
Ju, Xingzhu
Bi, Rui
Chen, Xiaojun
Yang, Wentao
Wu, Xiaohua
author_sort Feng, Zheng
collection PubMed
description Clear cell carcinoma (CCC) of the abdominal wall is a rare and agressive disease. We aim to elucidate the clinical and prognostic characteristics of this disease. Medical records of ten patients diagnosed with CCC of the abdominal wall at Fudan University Shanghai Cancer Center were reviewed. We illustrate the clinical characteristics, treatment modality, and development of local recurrence or distant metastasis, as well as the survival outcome. The median (range) age of patients was 47 (39–61) years old. All patients had a history of cesarean section and abdominal wall endometriosis. All patients had primary surgery before referred to our center. Seven patients had only tumor resection, while two patients had lymph node metastasis at primary diagnosis. Four patients underwent supplementary surgery, and all postoperative pathology were negative. Genetic analyses had also been performed. The median (range) follow-up time was 20 (12–59) months. Local recurrence and lymph node metastasis were the most common recurrence types. The median (95% confidence interval) PFS was 11 (8.08–13.92) months. In summary, primary surgery should consider wide tumor resection and lymph node dissection. Adjuvant chemotherapy and radiotherapy should be recommended for potential benefits. More cases are still needed to elucidate the clinical management of this disease.
format Online
Article
Text
id pubmed-9233660
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-92336602022-06-27 Treatment for clear cell carcinoma of the abdominal wall at a tertiary cancer center Feng, Zheng Wen, Hao Ju, Xingzhu Bi, Rui Chen, Xiaojun Yang, Wentao Wu, Xiaohua Sci Rep Article Clear cell carcinoma (CCC) of the abdominal wall is a rare and agressive disease. We aim to elucidate the clinical and prognostic characteristics of this disease. Medical records of ten patients diagnosed with CCC of the abdominal wall at Fudan University Shanghai Cancer Center were reviewed. We illustrate the clinical characteristics, treatment modality, and development of local recurrence or distant metastasis, as well as the survival outcome. The median (range) age of patients was 47 (39–61) years old. All patients had a history of cesarean section and abdominal wall endometriosis. All patients had primary surgery before referred to our center. Seven patients had only tumor resection, while two patients had lymph node metastasis at primary diagnosis. Four patients underwent supplementary surgery, and all postoperative pathology were negative. Genetic analyses had also been performed. The median (range) follow-up time was 20 (12–59) months. Local recurrence and lymph node metastasis were the most common recurrence types. The median (95% confidence interval) PFS was 11 (8.08–13.92) months. In summary, primary surgery should consider wide tumor resection and lymph node dissection. Adjuvant chemotherapy and radiotherapy should be recommended for potential benefits. More cases are still needed to elucidate the clinical management of this disease. Nature Publishing Group UK 2022-06-25 /pmc/articles/PMC9233660/ /pubmed/35752641 http://dx.doi.org/10.1038/s41598-022-14917-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Feng, Zheng
Wen, Hao
Ju, Xingzhu
Bi, Rui
Chen, Xiaojun
Yang, Wentao
Wu, Xiaohua
Treatment for clear cell carcinoma of the abdominal wall at a tertiary cancer center
title Treatment for clear cell carcinoma of the abdominal wall at a tertiary cancer center
title_full Treatment for clear cell carcinoma of the abdominal wall at a tertiary cancer center
title_fullStr Treatment for clear cell carcinoma of the abdominal wall at a tertiary cancer center
title_full_unstemmed Treatment for clear cell carcinoma of the abdominal wall at a tertiary cancer center
title_short Treatment for clear cell carcinoma of the abdominal wall at a tertiary cancer center
title_sort treatment for clear cell carcinoma of the abdominal wall at a tertiary cancer center
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233660/
https://www.ncbi.nlm.nih.gov/pubmed/35752641
http://dx.doi.org/10.1038/s41598-022-14917-0
work_keys_str_mv AT fengzheng treatmentforclearcellcarcinomaoftheabdominalwallatatertiarycancercenter
AT wenhao treatmentforclearcellcarcinomaoftheabdominalwallatatertiarycancercenter
AT juxingzhu treatmentforclearcellcarcinomaoftheabdominalwallatatertiarycancercenter
AT birui treatmentforclearcellcarcinomaoftheabdominalwallatatertiarycancercenter
AT chenxiaojun treatmentforclearcellcarcinomaoftheabdominalwallatatertiarycancercenter
AT yangwentao treatmentforclearcellcarcinomaoftheabdominalwallatatertiarycancercenter
AT wuxiaohua treatmentforclearcellcarcinomaoftheabdominalwallatatertiarycancercenter